Trial
NCT04969861
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Nektar Therapeutics
Collaborators
SFJ Pharmaceuticals, Inc.; Merck Sharp & Dohme LLC
Condition
Metastatic Head and Neck Cancer
Intervention
Bempegaldesleukin
Why stopped
Nektar Therapeutics made the decision to discontinue the bempegaldesleukin program based on three negative studies. SFJ Pharmaceuticals, Inc. and Nektar Therapeutics, in consultation with the study IDMC, have decided to discontinue PROPEL-36.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-01-12